Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study

Xavier Mariette*, Frauke Forger, Bincy Abraham, Ann D. Flynn, Anna Molto, Rene-Marc Flipo, Astrid van Tubergen, Laura Shaughnessy, Jeff Simpson, Marie Teil, Eric Helmer, Maggie Wang, Eliza F. Chakravarty

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)228-233
Number of pages6
JournalAnnals of the Rheumatic Diseases
Volume77
Issue number2
DOIs
Publication statusPublished - 1 Feb 2018

Keywords

  • anti-tnf
  • spondyloarthritis
  • rheumatoid arthritis
  • psoriatic arthritis
  • treatment
  • INFLAMMATORY-BOWEL-DISEASE
  • NECROSIS FACTOR-ALPHA
  • RHEUMATOID-ARTHRITIS
  • IMMUNE-SYSTEM
  • TNF-ALPHA
  • ANTIRHEUMATIC DRUGS
  • BIRTH OUTCOMES
  • WOMEN
  • METAANALYSIS
  • LACTATION
  • Prospective Studies
  • Humans
  • Infant
  • Luminescent Measurements/methods
  • Autoimmune Diseases/drug therapy
  • Young Adult
  • Product Surveillance, Postmarketing
  • Adult
  • Female
  • Infant, Newborn
  • Certolizumab Pegol/adverse effects
  • Pregnancy
  • Fetal Blood/chemistry
  • Placenta
  • Adolescent
  • Antirheumatic Agents/adverse effects

Cite this